Novel triple therapy eradicates Helicobacter pylori
A new three-drug combination therapy for the treatment of Helicobacter pylori infection is currently in phase 3 clinical trials. The combination RHB-105, consisting of amoxicillin (3 g), omeprazole (120 mg), and rifabutin (150 mg) in a single-dose capsule, achieved high eradication rates of H. pylori infection. [Ann Intern Med 2020;172(12):795–802]
